Better Outcomes
Improved Lives™

The SynerFuse® e-TLIF™ procedure, a ULE™ Therapy (Ultra Low Energy), is being studied to address chronic low back and leg pain for spinal fusion patients.

Clinical Research

Diagram of the e-TLIF procedure: a lumbar interbody fusion with a stimulation lead placed at the dorsal root ganglion on the same spinal level, connected to an implanted pulse generator.

The Problem in the United States with Chronic Low Back Pain and Opioids

Illustration of the lower back with the lumbar region highlighted.

619 Million

lives affected¹

1 Million+

lumbar fusions²

In SynerFuse’s own study, opioid use among the 15 participants fell to 20% by 12 weeks.⁵

Prescription tablets spilling from an open bottle.

45,008

annual deaths³

$134.5 Billion

annual cost⁴

Up to 28% still have chronic back or leg pain after a technically successful fusion.⁵

GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatology 2023;5(6):e316–e329 — 619 million people affected in 2020.
Ng MK, Mastrokostas LE, Mastrokostas PG, et al. Inpatient national trends and aggregate costs of primary and revision lumbar fusion in the US from 2016 to 2022. The Spine Journal 2026;26(9):1737–1746 — 1,029,610 primary and 183,110 revision procedures, National Inpatient Sample.
CDC, Vital Statistics Rapid Release provisional drug overdose death counts — 45,008 opioid-involved deaths (ICD-10 T40.0–T40.4, T40.6) in the 12 months ending December 2025.
Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996–2016. JAMA 2020;323(9):863–884 — $134.5 billion for low back and neck pain in 2016, the highest of 154 conditions.
Park MC, Lall RR, Reddy D, Sembrano JN, Falowski SM, Haider NR. Integrating dorsal root ganglion stimulation with transforaminal lumbar interbody fusion: proof of concept study. North American Spine Society Journal. 2026;27:100906. Uncontrolled case series, n=15, proof of concept; every author reports a financial relationship with SynerFuse, Inc. Read the paper.

These figures describe the disease state and the market. They are not claims about the performance of any SynerFuse product, which is investigational and not cleared or approved by the FDA.